Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · Prilosec, Losec, Zegerid (1)

Classic Psychedelic (1) · Dissociative (1) · Phenethylamine (1) · Research material (2) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:Proton_pump_inhibitors|Proton pump inhibitor (PPI)]] (1)

Extremely potent 5-HT2A agonist; vasoconstrictor (1) · NMDA antagonist; fluorinated ketamine analogue (1) · '"`UNIQ--vote-000000D8-QINU`"' Recovery of acid output requires synthesis of new pump enzyme. CYP2C19 substrate; PGx genotype substantially affects exposure and efficacy'"`UNIQ--ref-000000D9-QINU`"'. (1)

None (2) · '"`UNIQ--vote-000000DA-QINU`"', '"`UNIQ--vote-000000DB-QINU`"', '"`UNIQ--vote-000000DC-QINU`"', '"`UNIQ--vote-000000DD-QINU`"' (1)

None (2) · 20 mg PO once daily 30-60 minutes before breakfast (1)

None (2) · 10, 20, 40 mg delayed-release capsules and tablets; 2 mg/mL oral suspension; immediate-release combo with sodium bicarbonate (Zegerid) (1)

None (2) · 40 mg/d typical; up to 360 mg/d for Zollinger-Ellison (1)

None (2) · IV (1) · Oral (1)

None (2) · Symptom relief 1-4 days; full acid suppression after 3-5 days of dosing (1)

None (2) · 24-72 hours per dose (irreversible enzyme binding; effect outlasts plasma exposure) (1)

None (2) · 0.5-1.5 hours (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-000000DE-QINU`"' (1)

None (2) · 30-40% (oral; increases with repeated dosing as gastric pH rises)'"`UNIQ--ref-000000DF-QINU`"' (1)

None (2) · Widely used in pregnancy; meta-analyses do not show increased malformation risk.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (2) · OTC (20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1)